What the FDA labels say about taking them together
Pimavanserin and ziprasidone
Pimavanserin's FDA label of June 18, 2026 names ziprasidone in its warnings and precautions section; ziprasidone's label does not name pimavanserin itself but warns about its class (Atypical antipsychotics). The pimavanserin label: “The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain …”
Check it at the source: the pimavanserin FDA label on DailyMed (effective June 18, 2026, Acadia Pharmaceuticals Inc.); the ziprasidone FDA label on DailyMed (effective July 20, 2026, Apotex Corp.).
What does the pimavanserin label say about ziprasidone?
Pimavanserin label, warnings and precautionsThe use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin, moxifloxacin) [see Drug Interactions (7.1) ].
Source: FDA drug label (NUPLAZID), Acadia Pharmaceuticals Inc., effective June 18, 2026 (SPL set 1e6bea44-57d6-4bac-9328-46e1ee59f83b), via openFDA; the full label on DailyMed
What does the ziprasidone label say about pimavanserin?
Ziprasidone's label does not name pimavanserin itself; it warns about its class (Atypical antipsychotics):
Ziprasidone label, boxed warningINCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
Ziprasidone label, boxed warningElderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
Source: FDA drug label (ziprasidone hydrochloride), Apotex Corp., effective July 20, 2026 (SPL set ccfd5ba2-7271-f3dd-4c98-7418c1a4b54a), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Pimavanserin | Ziprasidone | |
|---|---|---|
| Labeled for | n/a | Bipolar disorder, Schizophrenia |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $170.50 per capsule 34 mg capsule | $0.269 per capsule 20 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once